Tariffs, capacity and the GLP-1 hire nobody planned for

Two years into the GLP-1 manufacturing scramble, most CDMOs have a fairly clear picture of where their talent gaps sit: peptide chemists, bioprocess engineers, sterile fill-finish specialists, quality staff who understand aseptic environments end to end. What wasn't on that list twelve months ago is trade compliance.

US trade policy has quietly turned into one of the biggest new cost lines in pharmaceutical manufacturing. In October 2025, the US floated tariffs on imported branded and patented pharmaceuticals as steep as 100%, tied to pricing commitments for channels like Medicaid and cash-pay programmes. Companies with a US manufacturing footprint, or a firm commitment to build one, got a route to exemption. Everyone else spent the back half of 2025 front-loading production and stockpiling inventory to get ahead of whatever came next. Pharmaceutical manufacturing output reportedly rose by just over 9% that year, well above the underlying trend, largely down to that rush to stock up before the rules changed.

Heading into 2026, the risk hasn't gone away, but it's narrowed for companies willing to commit to US investment or agree pricing terms that qualify for relief. For CDMOs and their sponsors, that means supply networks are being redrawn in real time. Some capacity is moving to North America. Some is doubling up across regions so no single site becomes a single point of exposure. All of it comes with more customs paperwork, more product classification work, and considerably more room for an expensive mistake.

That last point matters more for GLP-1 manufacturing than almost anywhere else in the sector. These are genuinely complex supply chains: the peptide API is often synthesised in one country, formulated in another, and filled into pens or syringes somewhere else again. Country of origin isn't a simple question when a product has passed through several jurisdictions before it reaches a patient. Get the tariff classification wrong, or misjudge where the substantial transformation actually happened, and the difference can be a duty-free shipment or one facing a triple-digit tariff at the border.

Which is why trade compliance specialists have gone, almost overnight, from a lean back-office function to a role CDMOs are actively recruiting for, in some cases for the first time. Job postings for the role increasingly list tariff classification, customs valuation and country-of-origin analysis alongside the more familiar demands around FDA and customs coordination. It's telling that several of these postings are explicitly open to candidates moving in from logistics, customs brokerage or general regulatory affairs, rather than holding out for a ready-made specialist. Pharma-specific trade compliance experience at this level of scrutiny simply hasn't existed in the numbers the industry now needs.

For anyone building out GLP-1 capacity, that's worth folding into the hiring plan now rather than discovering it mid-scale-up. The manufacturing and quality hires were always going to be hard to find. A workforce plan built purely around peptide synthesis and fill-finish headcount is missing a function that's become just as operationally load-bearing as either of them.

We've written before about the wider GLP-1 talent picture and where the real capacity bottlenecks sit. Tariffs are the piece that's changed since then, and they're quietly reshaping which roles actually sit on the critical path.